Rituximab is estimated to dominate the global TTP market, holding about 27.4% of the entire market by 2030, due to its increasing acceptance for prophylaxis and treatment of TTP. https://www.datamintelligence.com/research-report/thrombotic-thrombocytopenic-purpura-market